T1	Participants 45 123	patients with chronic hepatitis C treated with interferon-alpha and ribavirin:
T2	Participants 300 409	patients with chronic hepatitis C during and after treatment with interferon-alpha (IFN-alpha) and ribavirin.
T3	Participants 503 557	previously untreated patients with chronic hepatitis C
T4	Participants 953 1002	patients in the control and the amantadine group.
